PSA 2010 - Entering into a new era of early detection of prostate cancer;PSA 2010 - Aufbruch in eine neue ära der früherkennung des prostatakarzinom

Urologe - Ausgabe A

Volumn 45, Issue SUPP. 4, 2006, Pages 127-133

  Borgermann C ^g   Sieverding, M ^a   Fornara, P ^b   Graefen, M ^c   Hammerer, P ^d   Semjonow, A ^e   Schroder F ^f   Rubben H ^g  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d KLINIKUM BRAUNSCHWEIG   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER SCREENING; HUMAN; MORTALITY; PROSTATE CANCER; REVIEW; SEXUAL FUNCTION;

AGED; ALGORITHMS; BIOPSY, NEEDLE; CELL TRANSFORMATION, NEOPLASTIC; EARLY DIAGNOSIS; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748749168     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-006-1173-9     Document Type: Review

References (34)

1. Albertsen PC, Fryback DG, Storer BE et al. (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156(1): 127-132
2. American Cancer Society (2005) Cancer Facts & Figures (http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf
3. Aus G, Hugosson J, Norlen L (1995) Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154(2 Pt 1): 460-465
4. Berger AP, Deibl M, Steiner H et al. (2005) Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64(3): 240-245
5. Bill-Axelson A, Holmberg L, Ruutu M et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352(19): 1977-1984
6. Brawer MK, Chetner MP (1997) Campell's Urology. In: Walsh PC, Retik A, Stamey TA, Vaughan EJ (eds) Saunders, Philadelphia, pp 2506-2518
7. Catalona WJ, Richie JP, Ahmann FR et al. (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151(5): 1283-1290
8. Catalona WJ, Loeb S (2005) The PSA era is not over for prostate cancer. Eur Urol 48(4): 541-545
9. De Koning HJ, Liem MK, Baan CA et al. (2002) Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 98(2): 268-273
10. Essink-Bot ML, De Koning HJ, Nijs HG et al. (1998) Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 90(12): 925-931
11. Fachgesellschaften (2002) Arbeitsgemeinschaft wissenschaftlich medizinischer Fachgesellschaften. S3-Leitlinie: PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms)http://www. awmf-online.de
12. Gosselaar C, Roobol MJ, Schroder FH (2005) Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 95(2): 231-237
13. Gustafsson O, Theorell T, Norming U et al. (1995) Psychological reactions in men screened for prostate cancer. Br J Urol 75(5): 631-636
14. Hoedemaeker RF, Rietbergen JB, Kranse R et al. (2000) Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol 164(2): 411-415
15. Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172(5 Pt 2): 48-50
16. Luboldt HJ, Altwein JE, Bichler KH et al. (1999) Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle. Urologe A 38(2): 114-123
17. Parker C (2004) Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5(2): 101-106
18. Perczek RE, Burke MA, Carver CS et al. (2002) Facing a prostate cancer diagnosis: who is at risk for increased distress? Cancer 94(11): 2923-2929
19. Pienta KJ (1997) Etiology, epidemiology and prevention of carcinoma of the prostate. In: Walsh PC, Retik A, Stamey TA, Vaughan EJ, (eds) Campell's Urology. Saunders, Philadelphia, pp 2489-2496
20. Potter SR, Carter HB (2000) The role of prostate-specific antigen velocity in prostate cancer early detection. Curr Urol Rep 1(1): 15-19
21. Price CP, Allard J, Davies G et al. (2001) Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 38(Pt 3): 188-216
22. Raaijmakers R, Wildhagen MF, Ito K et al. (2004) Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 63(2): 316-320
23. Roobol MJ, Roobol DW, Schroder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65(2): 343-346
24. Schmid HP, Riesen W, Prikler L (2004) Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 50(1): 71-78
25. Schröder FH, Van DC-K, De Koning HJ et al. (2000) Prostate cancer detection at low prostate specific antigen. J Urol 163(3): 806-812
26. Semjonow A, De Angelis G, Oberpenning F et al. (2000) The clinical impact of different assays for prostate specific antigen. BJU Int 86(5): 590-597
27. Semjonow A, Schmid HP (2002) The rise and fall of PSA: clinical implications of prostate specific antigen kinetics. Urol Res 30(2): 85-88
28. Semjonow A (2006) Unterschiede zwischen PSA-Bestimmungsverfahren. In: Fornara P, Semjonow A (Hrsg) PSA: Der Weg zum Befund - Präanalytik und Analytik des prostataspezifischen Antigens. Zuckschwerdt, München
29. Soletormos G, Semjonow A, Sibley PE et al. (2005) Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 51(8):1342-1351
30. Stamey TA, Caldwell M, McNeal JE et al. (2004) The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172(4 Pt 1): 1297-1301
31. Steginga SK, Occhipinti S (2006) Dispositional optimism as a predictor of men's decision-related distress after localized prostate cancer. Health Psychol 25(2): 135-143
32. Stephan C, Klaas M, Muller C et al. (2006) Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 52(1): 59-64
33. van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH (2003) Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 95(19): 1462-1466
34. Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1152(5 Pt 2): 1831-1836